Braveheart Bio’s (BRVE) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Braveheart Bio (NASDAQ:BRVE) in a research note issued to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $40.00 target price on the stock.

Several other research analysts have also recently issued reports on the stock. Wall Street Zen raised shares of Braveheart Bio to a “hold” rating in a report on Saturday, August 15th. Jefferies Financial Group started coverage on shares of Braveheart Bio in a research note on Monday, August 31st. They issued a “buy” rating and a $48.00 target price on the stock. The Goldman Sachs Group assumed coverage on shares of Braveheart Bio in a report on Monday, August 31st. They set a “buy” rating and a $48.00 price target on the stock. Stifel Nicolaus initiated coverage on shares of Braveheart Bio in a research report on Monday, August 31st. They set a “buy” rating and a $45.00 price target for the company. Finally, Zacks Research upgraded shares of Braveheart Bio to a “hold” rating in a report on Tuesday, September 1st. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $45.25.

Braveheart Bio Stock Up 2.1%

Shares of NASDAQ:BRVE opened at $21.48 on Tuesday. The firm’s fifty day moving average is $24.22. Braveheart Bio has a 1-year low of $17.86 and a 1-year high of $32.00.

Braveheart Bio (NASDAQ:BRVE) last announced its quarterly earnings results on Tuesday, September 8th. The company reported ($2.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($2.26). On average, sell-side analysts predict that Braveheart Bio will post -1.99 EPS for the current fiscal year.

Insider Activity

In other Braveheart Bio news, Director Christopher Viehbacher acquired 83,333 shares of Braveheart Bio stock in a transaction that occurred on Friday, August 7th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $1,499,994.00. Following the acquisition, the director owned 609,519 shares of the company’s stock, valued at $10,971,342. This represents a 15.84% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Erez Chimovits acquired 1,940,000 shares of Braveheart Bio stock in a transaction that occurred on Friday, August 7th. The stock was acquired at an average price of $18.00 per share, with a total value of $34,920,000.00. Following the completion of the acquisition, the director directly owned 11,901,826 shares in the company, valued at $214,232,868. This represents a 19.47% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders purchased 8,751,942 shares of company stock valued at $157,534,956.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.